Breakthrough research expands formulation versatility for the most widely studied galactooligosaccharide prebiotic
Clasado Biosciences (‘Clasado’), a global leader in the development of scientifically proven prebiotic ingredients and product solutions for the gut microbiome, has announced its award-winning Bimuno® GOS, demonstrates a prebiotic effect at a low dose from just 380mg of active galactooligosaccharides (GOS) as uncovered in new pre-publication research.
The breakthrough research confirms that Bimuno GOS delivers a statistically significant prebiotic effect at an ultra-low dose, opening the door to new application opportunities for health and nutrition brands. This makes it a standout choice for product developers working with application formats as small as size 00 capsules, enabling the delivery of a proven prebiotic effect in a single low dose format. As the GOS with the lowest clinically supported dose of its kind for the general population, this latest development demonstrates exciting potential for the future.
Dr Lucien Harthoorn, R&D Director at Clasado Biosciences, commented: “This exciting new research demonstrates that even at remarkably low doses, Bimuno GOS continues to deliver its core prebiotic functionality. The study showed that at just 380mg of active GOS, we still see significant increases in beneficial bifidobacteria in the gut microbiome, the production of beneficial short-chain fatty acids (SCFAs), and lowering of intestinal pH – all key markers of prebiotic activity. The study, which we hope to see published later in the year, will provide more detailed findings on these exciting results.
“While doses from 1.37g of Bimuno GOS are supported by a range of clinically substantiated health benefits in areas such as gastrointestinal, immune and cognitive health, this new research delivers an important finding. It confirms that even at a significantly lower dose, Bimuno GOS’s unique structure helps it to achieve its fundamental bifidogenic effect, the nourishing of beneficial bacteria in the gut microbiome. This represents a major advancement for formulators working with specific delivery formats.”
The research demonstrated several key benefits from an ultra-low dose of Bimuno GOS, including increased bifidobacteria levels, enhanced production of SCFAs including butyrate and acetate, and a reduction of pH. Importantly, the study also showed that the utilisation of GOS by bifidobacteria accelerates over time, supporting Bimuno’s clinically proven rapid onset of action.
Dr Frederic Narbel, VP of Sales at Clasado, added: “The confirmation of Bimuno GOS prebiotic activity at ultra-low doses dramatically expands formulation possibilities for our partners. This creates new opportunities in applications where space is limited, while maintaining the scientific integrity that Bimuno GOS is known for.
“With over 125 scientific publications supporting Bimuno GOS including more than 20 clinical studies, this latest addition further establishes it as the prebiotic GOS with the lowest effective dose on the market. For health brands looking to develop scientifically supported gut health products, Bimuno GOS offers a significant competitive advantage.”
Formulators interested in learning more about Bimuno GOS are encouraged to speak with the Clasado team at upcoming industry exhibitions, including Natural Products Expo West in Anaheim California, USA (March 5-9) and Food Ingredients China 2025, Shanghai, China (March 17-19).
For more information about Bimuno GOS, please click here.
